Showing 15 posts of 23 posts found.


Acasti’s shares plunge as new drug does not meet primary endpoint

January 14, 2020
Manufacturing and Production Acasti, Acasti Pharma, CaPre, Primary Endpoint, Shares

Acasti Pharma’s shares plunged by as much as 67% this week as its drug CaPre failed to meet its primary …


Novartis exec sold off shares before Zolgensma data scandal was revealed

August 19, 2019
Sales and Marketing AveXis, Novartis, Shares, Zolgensma, pharma, stock market

An unnamed Novartis executive sold 925,400 Swiss francs (£778,665) worth of shares in the firm just weeks before the FDA …


Novo Holdings invests £53.5 million into Oxford Biomedica

May 30, 2019
Business Services, Sales and Marketing Novo Holdings, Novo Nordisk, Oxford BioMedica, Shares, cell and gene therapy, lentivirus

Novo Holdings has agreed to buy 10.1% of shares in British firm Oxford Biomedica for £53.5 million. Novo will buy …


ImmunoGen shares plummet by 32% after FDA recommends new Phase 3 trial

May 16, 2019
Business Services, Research and Development Cancer, Immunogen, Shares, ovarian cancer, pharma, stocks

Shares in ImmunoGen fell 32% in premarket trading after the firm said the FDA had recommended a new Phase 3 …


Gilead shares drop 4% after failure of NASH drug to meet primary endpoint

February 12, 2019
Manufacturing and Production Gilead, Shares, fatty liver disease, nash, selonsertib

Gilead’s treatment for the progressive fatty liver disease, NASH, has failed to meet its primary goal in a phase 3 …


J&J announces $5bn share repurchase

December 18, 2018
Manufacturing and Production J&J, JJ, Shares, asbestos, baby powder, reuters, scandal

New Jersey-based pharma firm Johnson & Johnson plans to buy back $5 billion in shares after news agency Reuters released …


Samsung Biologics shares fall by 20% after Korean investigation

November 13, 2018
Manufacturing and Production Shares, accounting, pharma, smasung biologics, stockmarket

Shares in Korean firm Samsung BioLogics plummeted this week, falling by as much as 20% on Monday, after the South …


Pharma stocks soar after US midterm elections

November 8, 2018
Business Services, Manufacturing and Production Shares, Stock, Trump, biotech, pharma, stock market

Despite the threat of a bipartisan pricing plan, pharma stocks have soared after the announcement of the results of the …

Shares in Molecular Templates surge after the announcement of Takeda collaboration

September 20, 2018
Business Services, Research and Development Molecular Templates, Shares, Takeda, markets, stocks

Shares in the Texas based biotech Molecular Templates have soared after the company announced that they would be collaborating with …

Realm Therapeutics shares halved after failure of Phase 2 study

August 15, 2018
Research and Development London, Shares, atopic dermatitis, phase 2, stock market

Shares in the London-listed Realm Therapeutics plummeted on Monday after the company reported that a Phase II study of the …


Regeneron Pharma and Bluebird bio announce immune cell collaboration

August 6, 2018
Sales and Marketing Cancer, Regeneron, Shares, bluebird, collaboration, t cells, t-cells

Regeneron Pharmaceuticals have announced that they will collaborate with the Massachusetts-based gene therapy specialist Bluebird bio in an effort to …


Weekly Movers: Regulus, Nymox, Akers…

July 4, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shares, drug trial, markets, stocks

Shares in Regulus Therapeutics (Nasdaq: RGLS) dropped after the company said it has received verbal notification from the US Food …


Immunomedics’ chief financial officer resigns, shares fall

June 22, 2016
Research and Development, Sales and Marketing Immunomedics, Shares, cfo, stock market

Shares in Immunomedics (Nasdaq: IMMU) fell as much as 11% after the company said its chief financial officer Peter Pfreundschuh …

Latest content